Cambium BioASX:CMB 35 Cash Ratio is 1.60 as of Dec. 2025, which is 233% above its 10-year median of 0.48. GuruFocus rates ASX:CMB with a GF Score™ of 35/100. The stock has 4 warning signs investors should review. Among 1,386 Biotechnology companies, Cambium Bio ranks worse than 65.3% on this metric.
Cambium Bio has a Cash Ratio of 1.60. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Cambium Bio's Cash Ratio or its related term are showing as below:
ASX:CMB'
s Cash Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.48 Max: 7.29
Current: 1.6
During the past 12 years, Cambium Bio's highest Cash Ratio was 7.29. The lowest was 0.02. And the median was 0.48.
ASX:CMB's Cash Ratio is ranked worse than 65.3% of 1386
companies
in the Biotechnology industry
Industry Median: 2.93
vs ASX:CMB: 1.60
Cambium Bio (ASX:CMB) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Cambium Bio Cash Ratio Related Terms
Cambium Bio Cash Ratio Historical Data
* Premium members only.
The historical data trend for Cambium Bio's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CMB vs VRTX, REGN, ALNY: Cash Ratio Comparison
For the Biotechnology subindustry, Cambium Bio's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambium Bio Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cambium Bio's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Cambium Bio's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambium Bio (ASX:CMB) has a Cash Ratio of 1.60 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cambium Bio and its competitors. This is 233% above median its historical median of 0.48. Over the past decade, Cambium Bio's Cash Ratio has ranged from 0.02 to 7.29. According to the industry distribution chart, Cambium Bio ranks #905 out of 1386 companies in the Biotechnology industry, placing it in the top 65.3%.
Is Cambium Bio's Cash Ratio too high?
Cambium Bio's current Cash Ratio of 1.60 is 233% above median its 10-year median of 0.48. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 7.29. The Biotechnology industry median Cash Ratio is 2.93. Cambium Bio's value of 1.60 is 45.4% below this industry median. Based on the distribution chart, Cambium Bio ranks #905 out of 1386 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cambium Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cambium Bio ranks #905 out of 1386 companies for Cash Ratio. This places Cambium Bio in the lower half of its industry. The industry median Cash Ratio is 2.93. Cambium Bio's value of 1.60 is 45.4% below this benchmark. Historically, Cambium Bio's own Cash Ratio has ranged from 0.02 to 7.29 over the past decade. While the company's 10-year median is 0.48 vs. the industry median of 2.93, Cambium Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,386 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cambium Bio's current Cash Ratio of 1.60 is 45.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cambium Bio and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambium Bio's current Cash Ratio is 1.60, which is 233% above median its own 10-year median of 0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current Cash Ratio of 1.60. The current Cash Ratio is 1.60, which is 233% above median its 10-year median of 0.48 and 45.4% below the Biotechnology industry median of 2.93. Cambium Bio's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current Cash Ratio is 1.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
35GF Score
Get the complete analysis for ASX:CMB
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMB has been successfully added to your 
